On Tuesday, NovoCure Ltd (NASDAQ: NVCR) was 8.76% up from the session before settling in for the closing price of $16.90. A 52-week range for NVCR has been $14.17 – $34.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 11.49% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -4.67%. With a float of $99.05 million, this company’s outstanding shares have now reached $111.48 million.
In an organization with 1488 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 77.16%, operating margin of -26.84%, and the pretax margin is -20.88%.
NovoCure Ltd (NVCR) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward NovoCure Ltd stocks. The insider ownership of NovoCure Ltd is 11.15%, while institutional ownership is 85.15%. The most recent insider transaction that took place on Jun 03 ’25, was worth 17,259. In this transaction Director of this company sold 999 shares at a rate of $17.28, taking the stock ownership to the 3,054 shares. Before that another transaction happened on Jun 03 ’25, when Company’s Director sold 999 for $17.31, making the entire transaction worth $17,297. This insider now owns 81,229 shares in total.
NovoCure Ltd (NVCR) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.43 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.60% during the next five years compared to -83.87% drop over the previous five years of trading.
NovoCure Ltd (NASDAQ: NVCR) Trading Performance Indicators
You can see what NovoCure Ltd (NVCR) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.51, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of NovoCure Ltd (NVCR)
Let’s dig in a bit further. During the last 5-days, its volume was 1.82 million. That was better than the volume of 1.01 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.42%. Additionally, its Average True Range was 1.05.
During the past 100 days, NovoCure Ltd’s (NVCR) raw stochastic average was set at 28.20%, which indicates a significant decrease from 56.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.06% in the past 14 days, which was higher than the 58.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.45, while its 200-day Moving Average is $20.21.
